Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) EBITDA (2021 - 2026)

HeartSciences' EBITDA history spans 6 years, with the latest figure at -$1.9 million for Q1 2026.

  • For Q1 2026, EBITDA rose 18.66% year-over-year to -$1.9 million; the TTM value through Jan 2026 reached -$7.8 million, up 6.2%, while the annual FY2025 figure was -$8.4 million, 32.46% down from the prior year.
  • EBITDA reached -$1.9 million in Q1 2026 per HSCS's latest filing, up from -$2.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$1.1 million in Q1 2022 to a low of -$2.4 million in Q1 2025.
  • Average EBITDA over 5 years is -$1.7 million, with a median of -$1.9 million recorded in 2025.
  • Peak YoY movement for EBITDA: tumbled 112.04% in 2022, then grew 19.17% in 2023.
  • A 5-year view of EBITDA shows it stood at -$1.8 million in 2022, then grew by 11.55% to -$1.6 million in 2023, then dropped by 26.44% to -$2.0 million in 2024, then dropped by 4.45% to -$2.1 million in 2025, then grew by 6.97% to -$1.9 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's EBITDA are -$1.9 million (Q1 2026), -$2.1 million (Q4 2025), and -$1.9 million (Q3 2025).